These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1081 related articles for article (PubMed ID: 22466476)

  • 21. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
    Inoue M; Arakawa A; Yamane S; Kadonosono K
    Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
    Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
    Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
    Tao Y; Jonas JB
    Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gray hyper-reflective subretinal exudative lesions in exudative age-related macular degeneration.
    Ores R; Puche N; Querques G; Blanco-Garavito R; Merle B; Coscas G; Oubraham H; Semoun O; Souied EH
    Am J Ophthalmol; 2014 Aug; 158(2):354-61. PubMed ID: 24794284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
    Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography.
    Framme C; Panagakis G; Birngruber R
    Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1671-6. PubMed ID: 19875667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Chan CK; Meyer CH; Gross JG; Abraham P; Nuthi AS; Kokame GT; Lin SG; Rauser ME; Kaiser PK
    Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration.
    Parodi MB; Iacono P; La Spina C; Iuliano L; Lo Giudice G; Introini U; Bandello F
    Retina; 2014 Nov; 34(11):2167-70. PubMed ID: 24999724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intravitreal ranibizumab injection for the treatment of idiopathic choroidal neovascularisation in young patients].
    Ouhadj O; Degheb N; Idir S; Nebab A; Nouri MT
    J Fr Ophtalmol; 2012 Sep; 35(7):514-22. PubMed ID: 22789650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration.
    Zweifel SA; Engelbert M; Khan S; Freund KB
    Retina; 2009; 29(10):1527-31. PubMed ID: 19898185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
    Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
    Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab.
    Sayanagi K; Sharma S; Yamamoto T; Kaiser PK
    Ophthalmology; 2009 May; 116(5):947-55. PubMed ID: 19232732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results.
    Parravano M; Oddone F; Tedeschi M; Chiaravalloti A; Perillo L; Boccassini B; Varano M
    Retina; 2010; 30(7):1017-24. PubMed ID: 20224469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination treatment with intravitreal injection of ranibizumab and reduced fluence photodynamic therapy for choroidal neovascularization secondary to angioid streaks: preliminary clinical results of 12-month follow-up.
    Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Senel A; Bahcecioglu H
    Retina; 2011; 31(7):1279-86. PubMed ID: 21394063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
    Rothenbuehler SP; Waeber D; Brinkmann CK; Wolf S; Wolf-Schnurrbusch UE
    Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
    Engelbert M; Zweifel SA; Freund KB
    Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.